Drug Profile
Eldelumab
Alternative Names: Anti-CXCL10 antibody; Anti-IP10 antibody; BMS-936557; MDX-1100Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Medarex
- Developer Bristol-Myers Squibb; Medarex
- Class Antirheumatics; Antiulcers; Monoclonal antibodies
- Mechanism of Action Chemokine CXCL10 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Crohn's disease; Ulcerative colitis
- Discontinued Multiple sclerosis; Rheumatoid arthritis; Spinal cord injuries
Most Recent Events
- 04 Oct 2015 No recent reports of development identified - Phase-II for Ulcerative colitis in Russia, Ukraine, Poland, Romania, Mexico, Latvia, Mexico, Czech Republic, France, Netherlands, Hungary, Germany, Italy, Belgium, South Africa, Canada, Australia, Brazil, Austria, USA (IV)
- 04 Oct 2015 No recent reports of development identified - Phase-II for Crohn's disease (Treatment-experienced) in Poland, Israel, France, Belgium, Hungary, USA, Puerto Rico and South Africa (IV)
- 01 Dec 2014 Bristol-Myers Squibb completes a phase II trial in Crohn's disease in USA, Belgium, France, Hungary, Israel, Poland, Puerto Rico and South Africa (NCT01466374)